References
- Epps J. E., Ng K. T., Tuman R. W., Wu W. N. US Patent No. 4670436., 1987a, Hypoglycemic 5-substituted pyrrolidinylidene compounds, compositions and use.
- Epps J. E., Ng K. T., Tuman R. W., Wu W. N. US Patent No. 4716163, 1987b, Hypoglycemic method using 5-substituted pyrrolidinylidene compounds.
- Gardocki J. F., Hageman W. E., Pruss T. P. Pharmacological profile of N-(2,6- dimethylphenyl)-N'-(1-methyl-2-pyrrolidinylidene)urea, Xilobam, a new centrally acting skeletal muscle relaxant. Archives Internationales de Pharmacodynamie et de Therapie 1978; 233: 326–342
- Nelson S. D. Metabolic activation and drug toxicity. Journal of Medicinal Chemistry 1982; 25: 753–765
- Rasmussen C. R. US Patent No. 3876658, 1975
- Rasmussen C. R., Gardocki J. F., Plampin J. N., Twardzik B. L., Reynolds B. E., Molinari A. J., Schwartz N., Bennetts W. W., Price B. E., Marakowski J. 2-Pyrrolidinylideneureas, a new class of central nervous system agents. Journal of Medicinal Chemistry 1978; 21: 1044–1054
- Wu W. N., Hills J. F., Chang S. Y., Ng K. T. Metabolism of bepridil in laboratory animals and human. Drug Metabolism and Disposition 1988; 16(1)69–77
- Wu W. N., Hills J. F., Egan R. S., Ng K. T., Grindel J. M., O'Neill P. J. Isolation and identification of xilobam (Xm) metabolites in plasma (man) and urine (mouse, rat, dog, and man). Pharmacologist 1983; 25(3)381
- Wu W. N., Ng K. T., Mutter M. S. Metabolism of linogliride (Lg) in the rat, dog, and man. Federation Proceedings 1986; 45: 443
- Wu W. N., Pritchard J. F., Ng K. T., Hills J. F., Uetz J. A., Yorgey K. A., McKown L. A., O'Neill P. J. Disposition of bepridil in laboratory animals and man. Xenobiotica 1992; 22(2)153–169